Programs & products

The primary endpoint of the trial was met This is the first proof of concept in patients of an anti-viral effect of γδ T cell activation Innate Pharma intends to develop further its program in this...

IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009 Available on...

Innate Pharma S.A., a biopharmaceutical company specialized in cancer immuno- therapeutics, today announced the achievement of the first milestone in their collaboration with Novo Nordisk A/S in...

Innate Pharma SA announced today the entry into regulatory pre-clinical development of IPH 2201, a novel monoclonal antibody targeting NK (Natural Killer) cells. On this occasion, the Company updated...

Innate Pharma SA anounces that it has received approval from the French authorities to start an exploratory Phase II clinical trial in chronic myeloid leukemia ("CML") with IPH 1101.

Innate Pharma S.A. announced that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with the Company, was administered for the first time in patients suffering from multiple myeloma.

Innate Pharma S.A. has received approval for its phase II trial with IPH 1101 in Type C viral hepatitis.

Innate Pharma S.A. announced it has entered into a in-licensing agreement with Cancer Research Technology (CRT) on novel TLR agent.

Innate Pharma S.A. announced that a set of pharmacological data, from Research to clinical Phase II, of its drug candidate IPH 1101 was presented at the "American Society of Clinical Oncology" annual...